Fortress Biotech Inc (NASDAQ:FBIO) has been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.00.
FBIO has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Fortress Biotech in a research report on Tuesday, December 5th. Zacks Investment Research cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. Finally, ValuEngine cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
In other news, CEO Lindsay A. Md Rosenwald bought 40,000 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $25.00 per share, with a total value of $1,000,000.00. Following the transaction, the chief executive officer now directly owns 40,000 shares in the company, valued at $1,000,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP George Avgerinos sold 12,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $3.55, for a total value of $42,600.00. Following the sale, the senior vice president now directly owns 352,495 shares of the company’s stock, valued at $1,251,357.25. The disclosure for this sale can be found here. 33.30% of the stock is owned by corporate insiders.
Fortress Biotech (NASDAQ FBIO) traded up $0.01 during trading hours on Tuesday, hitting $4.20. The stock had a trading volume of 153,148 shares, compared to its average volume of 167,250. The firm has a market cap of $212.25, a PE ratio of -2.31 and a beta of 1.11. Fortress Biotech has a twelve month low of $2.19 and a twelve month high of $5.13. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.42.
Fortress Biotech (NASDAQ:FBIO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.24). The business had revenue of $46.89 million for the quarter, compared to analyst estimates of $50.75 million. Fortress Biotech had a negative return on equity of 61.43% and a negative net margin of 65.80%. The firm’s quarterly revenue was up 4709.2% on a year-over-year basis. research analysts forecast that Fortress Biotech will post -1.99 EPS for the current fiscal year.
About Fortress Biotech
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.